Clonal hematopoiesis of indeterminate potential (CHIP), particularly non-DNMT3A CHIP subtypes, is an independent risk factor for incident heart failure (HF) and may represent a novel therapeutic target. In a UK Biobank cohort of 417,616 adults (mean age, 56.1 years; 56.2% women) without prior HF or major comorbidities, 7,183 participants (1.7%) […]
Intracoronary infusion of Wharton’s jelly–derived mesenchymal stem cells after acute myocardial infarction (AMI) significantly reduced the risk of developing heart failure (HF) and related adverse cardiovascular events, suggesting its potential as a valuable adjunctive therapy. In a Iranian phase 3 randomized clinical trial involving 420 patients with a first ST-segment […]
An international, double-blind, placebo-controlled trial suggested that digitoxin modestly lowered the combined risk of death from any cause or hospital admission for worsening heart failure (HF) than placebo in patients with advanced HF receiving modern therapy. The trial evaluated digitoxin in 1,240 patients with chronic HF and reduced ejection fraction […]
A recent randomized crossover trial evaluated the efficacy and safety of combining dapagliflozin with spironolactone versus using dapagliflozin alone in patients with heart failure with mildly reduced or preserved ejection fraction. Involving 108 participants (median age 76, 57% women), estimated glomerular filtration rate (eGFR) 72 mL/min/1.73 m2，the 12-week study found […]